Canada · Series E startup
Funding summaryUpdated 26 Oct 2026
$71Mraised across 4 rounds since 2008, from 4 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Reported by onbiovc.comSEC filing: $3.9M sold, first sale May 2010
Reported by fiercebiotech.comSEC filing: $3.9M sold, first sale May 2010
No investor was named in the report.
From a historical funding recordSEC filing: $9.3M sold, first sale May 2009
BDC Capital
VantagePoint Capital Partners
H.I.G. Capital
Pinnacle Ventures
Sanderling Ventures
Fonds de solidarite Ftq
ProQuest Investments
Ontario Teachers' Pension Plan
HBM PartnersReported by siliconindia.com
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
From historical deal records. Wrong? Tell us.
Missing a round, or an investor who was in one? Tell us.
Gemin X Pharmaceuticals's investors include Sanderling Ventures, Caxton Advantage Life Sciences Fund, BDC Capital, VantagePoint Capital Partners and H.I.G. Capital, and 8 more on record.
Gemin X Pharmaceuticals has raised $71M across 4 rounds since 2008.
Gemin X Pharmaceuticals's most recent round was a Series E of $8.0M in Aug 2010.
Gemin X Pharmaceuticals's largest round on record is $38M (Series C), in Jul 2008.
Gemin X Pharmaceuticals's first round on record, in Jul 2008, was backed by BDC Capital, VantagePoint Capital Partners and H.I.G. Capital and 10 others.
Gemin X Pharmaceuticals's latest named round is a Series E, in Aug 2010.
Gemin X Pharmaceuticals is based in Canada.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
Canada · 
